| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Employment Agreement (“Agreement”) is made as of the Nineteenth (19th) day of October, 2026 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew J. Silver (the “Executive” and, together with the Comp... |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
ZUG, Switzerland and BOSTON, August 3, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. |
| 04 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
(Translation; in case of controversy the German text shall prevail) |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
ZUG, Switzerland and BOSTON, May 4, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. |
| 16 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
CRISPR THERAPEUTICS AGANDU.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION,as TrusteeINDENTUREDated as of March 16, 2026 |
| 11 Mar 2026 |
8-K: Other Events
ZUG, Switzerland and BOSTON, March 11, 2026 – CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the “notes”) in a privat... |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
ZUG, Switzerland and BOSTON, February 12, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. |
| 12 Jan 2026 |
8-K: Other Events
On January 12, 2026, CRISPR Therapeutics AG (the “Company”) issued a press release highlighting, among other things, selected updates related to its wholly-owned cardiovascular, autoimmune, immuno-oncology and regenerative medicine progr... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine- |
| 15 Oct 2025 |
8-K: Other Events
We have acted as Swiss counsel to CRISPR Therapeutics AG, Zug, Switzerland (the Company) on matters of Swiss law in connection with the Company’s filing of a registration statement on Form S-3 automatic shelf registration (as amended or ... |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition
-CASGEVY®momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong future growth- |
| 26 Jun 2025 |
8-K: Other Events
On June 26, 2025, CRISPR Therapeutics AG (the “Company”) announced updates across its in vivo cardiovascular disease programs. These include new data for CTX310™, targeting ANGPTL3, as well as continued progress on CTX320™, targeting the... |
| 09 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
(Translation; in case of controversy the German text shall prevail) |
| 19 May 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
[***] Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; pres... |
| 26 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
ZUG, Switzerland and BOSTON, March 26, 2025 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer... |
| 11 Feb 2025 |
8-K: Results of Operations and Financial Condition
-2025 is poised to be a catalyst-rich year with key updates across several programs- |
| 05 Nov 2024 |
8-K: Results of Operations and Financial Condition
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- |
| 05 Aug 2024 |
8-K: Results of Operations and Financial Condition
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- |
Loading...